IFN-alpha/beta R1 Antibody (2951C) [Unconjugated]

Western blot shows lysates of Daudi human Burkitt's lymphoma cell line and K562 human chronic myelogenous leukemia cell line. PVDF membrane was probed with 2 µg/mL of Rabbit Anti-Human IFN‑ alpha / beta R1 Monoclonal Antibody (Catalog # MAB2452) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for IFN‑ alpha / beta R1 at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

U937 cells were stained with Rabbit Anti-Human IFN‑ alpha / beta R1 Monoclonal Antibody (Catalog # MAB2452, filled histogram) or isotype control antibody (Catalog # MAB1050, open histogram), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0111). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: WB, Flow
• Clone: 2951C
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

IFN-alpha/beta R1 Antibody (2951C) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line, NS0-derived human IFN-alpha/beta R1
  Gly26-Lys436
  Accession # P17181
• Specificity: Detects human IFN‑ alpha / beta R1 in direct ELISA.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.10 ug/10^6 cells
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IFN-alpha/beta R1 Antibody (2951C) [Unconjugated]

• alpha-type antiviral protein
• AVP
• beta-type antiviral protein
• CRF2-1
• Cytokine receptor class-II member 1
• Cytokine receptor family 2 member 1
• human interferon-alpha receptor (HuIFN-alpha-Rec)10IFRC
• IFN-alpha/beta R1
• IFN-alpha/beta receptor 1
• IFN-alpha-REC
• IFNAR
• IFNAR1
• IFN-aR1
• IFNBR
• IFNbR1
• IFN-bR1
• IFN-R-1
• interferon (alpha, beta and omega) receptor 1
• interferon alpha/beta receptor 1
• interferon-alpha/beta receptor alpha chain
• interferon-beta receptor 1
• Type I interferon receptor 1

Background

Interferon‑alpha/beta receptor 1 (IFN‑ alpha / beta  R1), also known as IFNAR1, is a 100‑130 kDa member of the class II cytokine receptor family of proteins. These proteins form heterodimeric receptor complexes that mediate class II cytokine signals. Subunits of the different receptor complexes are shared and serve multiple functions (1). IFN‑ alpha / beta  R1, in association with IFN‑ alpha / beta  R2, is required for propagating anti‑microbial signal transduction triggered by the type 1 interferons such as IFN‑ alpha and IFN‑ beta (2, 3). Mature human IFN‑ alpha / beta  R1 consists of a 409 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 100 aa cytoplasmic domain (4). The ECD contains three tandem fibronectin type III repeats and is extensively glycosylated. Within the ECD, human IFN‑ alpha / beta  R1 shares 47% and 50% aa identity with mouse and rat  IFN‑ alpha / beta  R1, respectively. Alternative splicing generates two additional isoforms that lack the transmembrane segment and either all or a portion of the cytoplasmic domain. IFN‑ alpha / beta  R1 interacts very weakly or not at all with type 1 interferons and does not stably interact with IFN‑ alpha / beta  R2. Ligands preferentially associate with IFN‑ alpha / beta  R2, and this complex subsequently forms a stable ternary assembly with IFN‑ alpha / beta  R1 (5‑7). IFN‑ alpha / beta  R1 also associates with IFN‑ gamma  R2 even in the absence of IFN‑ gamma stimulation (3). IFN‑ alpha / beta  R1 activation depends on tyrosine phoshorylation as well as palmitoylation of its cytoplasmic domain (8, 9). Rapid down‑regulation of the receptor is accomplished by ligand‑dependent or ‑independent pathways (e.g. VEGF R signaling, TLR signaling, or cellular stress) which induce its serine phosphorylation, ubiquitination, and degradation (10‑13).

1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
2. Hwang, S.Y. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11284.
3. Takaoka, A. et al. (2000) Science 288:2357.
4. Uze, G. et al. (1990) Cell 60:225.
5. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
6. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
7. Kalie, E. et al. (2008) J. Biol. Chem. 283:32925.
8. Platanias, L.C. (2005) Nat. Rev. Immunol. 5:375.
9. Claudinon, J. et al. (2009) J. Biol. Chem. 284:24328.
10. Zheng, H. et al. (2011) Blood 118:4003.
11. Qian, J. et al. (2011) PLoS Pathogens 7:e1002065.
12. Bhattacharya, S. et al. (2010) J. Biol. Chem. 285:2318.
13. Bhattacharya, S. et al. (2011) J. Biol. Chem. 286:22069.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P17181()